180 related articles for article (PubMed ID: 28445481)
21. Irinotecan in the treatment of colorectal cancer.
Fuchs C; Mitchell EP; Hoff PM
Cancer Treat Rev; 2006 Nov; 32(7):491-503. PubMed ID: 16959432
[TBL] [Abstract][Full Text] [Related]
22. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
[TBL] [Abstract][Full Text] [Related]
23. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
Yu X; Li Z; Yu J; Chan MT; Wu WK
Cell Prolif; 2015 Oct; 48(5):503-10. PubMed ID: 26202377
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
25. Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors.
Pawlak A; Ziolo E; Fiedorowicz A; Fidyt K; Strzadala L; Kalas W
BMC Cancer; 2016 Nov; 16(1):893. PubMed ID: 27852227
[TBL] [Abstract][Full Text] [Related]
26. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.
Azad NS; El-Khoueiry A; Yin J; Oberg AL; Flynn P; Adkins D; Sharma A; Weisenberger DJ; Brown T; Medvari P; Jones PA; Easwaran H; Kamel I; Bahary N; Kim G; Picus J; Pitot HC; Erlichman C; Donehower R; Shen H; Laird PW; Piekarz R; Baylin S; Ahuja N
Oncotarget; 2017 May; 8(21):35326-35338. PubMed ID: 28186961
[TBL] [Abstract][Full Text] [Related]
27. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
28. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
29. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
[TBL] [Abstract][Full Text] [Related]
30. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
31. Caffeine enhances chemosensitivity to irinotecan in the treatment of colorectal cancer.
Yoon S; Lee BK; Kim KP
Phytomedicine; 2023 Dec; 121():155120. PubMed ID: 37806154
[TBL] [Abstract][Full Text] [Related]
32. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
Tosi D; Pérez-Gracia E; Atis S; Vié N; Combès E; Gabanou M; Larbouret C; Jarlier M; Mollevi C; Torro A; Del Rio M; Martineau P; Gongora C
BMC Cancer; 2018 Aug; 18(1):812. PubMed ID: 30103709
[TBL] [Abstract][Full Text] [Related]
33. GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer.
Pelosof L; Yerram S; Armstrong T; Chu N; Danilova L; Yanagisawa B; Hidalgo M; Azad N; Herman JG
Epigenetics; 2017 Jul; 12(7):540-550. PubMed ID: 27918237
[TBL] [Abstract][Full Text] [Related]
34. Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.
Nielsen DL; Palshof JA; Brünner N; Stenvang J; Viuff BM
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28880238
[TBL] [Abstract][Full Text] [Related]
35. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y
Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063
[TBL] [Abstract][Full Text] [Related]
36. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.
Fior R; Póvoa V; Mendes RV; Carvalho T; Gomes A; Figueiredo N; Ferreira MG
Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8234-E8243. PubMed ID: 28835536
[TBL] [Abstract][Full Text] [Related]
37. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
[TBL] [Abstract][Full Text] [Related]
38. New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy J; Hochster H
Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
[TBL] [Abstract][Full Text] [Related]
39. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
